EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma

I-Wei Ho iD, Nai-Jung Chiang, Jiun-I Lai iD, Peter Mu-Hsin Chang, San-Chi Chen, Yi-Ping Hung, Ming-Huang Chen iD

The Oncologist · 10.03.2025 · 30 (3)

DOI: 10.1093/oncolo/oyae372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.03.2025. Verfasst von I-Wei Ho und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan. Hauptthemen laut MEDLINE: Etoposide, Carcinoma, Neuroendocrine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiwan Cancer Clinic Foundation, Melissa Lee Cancer Foundation, Taipei Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neuroendocrine carcinoma (NEC) is an aggressive, poorly differentiated Grade 3 (G3) tumor with high nuclear and cellular atypia and Ki-67 indices over 20%. While most cases are lung NECs, extrapulmonary NECs are rarer and less studied. Standard treatment involves etoposide and platinum (EP) chemotherapy. Inspired by the IMpower133 study, which showed survival benefits with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer, this study investigates whether atezolizumab combined with platinum and etoposide can offer similar benefits for extrapulmonary NEC.

Method

This retrospective cohort study, conducted at Taipei Veterans General Hospital from January 2016 to June 2023, compared the efficacy of atezolizumab combined with platinum and etoposide versus standard chemotherapy alone in extrapulmonary NEC patients. The outcomes assessed were response rate, progression-free survival (PFS), and overall survival (OS).

Result

The study evaluated 56 patients: 14 received atezolizumab with platinum and etoposide (EP), while 42 were treated with EP alone. The median PFS was 5.2 months, and median OS was 11.9 months for the whole cohort. While there were no significant differences in OS or PFS between the groups, the response rate was significantly higher in the atezolizumab group. Additionally, a neutrophil-lymphocyte ratio (NLR) above 3 was linked to poorer OS.

Conclusion

The addition of atezolizumab to EP did not improve PFS and OS in extrapulmonary NEC patients but did result in a higher response rate. Moreover, an NLR above 3 at diagnosis was identified as a poor prognostic factor for OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtoposideCarcinoma, NeuroendocrineAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedPlatinumHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdult

Stichwörter der Autor:innen

atezolizumabetoposideextrapulmonary neuroendocrine carcinomaimmunotherapyneutrophil-lymphocyte ratiooverall survivalplatinumprogression-free survival

Substanzen

atezolizumabEtoposideAntibodies, Monoclonal, HumanizedPlatinum

Autor:innen und Institutionen

  • Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
  • School of Medicine, National Yang-Ming University, Taipei 112304, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
  • Chang Institute of Biopharmaceutical Science, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
  • Center of Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

ORCID-Profile: I-Wei Ho, Jiun-I Lai, Ming-Huang Chen

Förderung

  • Taiwan Cancer Clinic Foundation
  • Melissa Lee Cancer Foundation
  • Taipei Veterans General Hospital
  • Veterans General Hospitals
  • University System of Taiwan Joint Research Program
  • National Science and Technology Council

Zitieren

APA

Ho, I. W., Chiang, N. J., Lai, J. I., Chang, P. M., Chen, S. C., Hung, Y. P., & Chen, M. H. (2025). Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma. The Oncologist, 30(3). https://doi.org/10.1093/oncolo/oyae372

Vancouver

Ho IW, Chiang NJ, Lai JI, Chang PM, Chen SC, Hung YP, et al. Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma. The Oncologist. 2025;30(3). doi:10.1093/oncolo/oyae372

BibTeX
@article{Ho2025,
  author = {Ho, I-Wei and Chiang, Nai-Jung and Lai, Jiun-I and Chang, Peter Mu-Hsin and Chen, San-Chi and Hung, Yi-Ping and Chen, Ming-Huang},
  title = {Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {3},
  doi = {10.1093/oncolo/oyae372}
}
Kostenlos starten →